SCN3A
Sodium channel protein type 3 subunit alpha
As of the edition of 20 October 2026, SCN3A (sodium channel protein type 3 subunit alpha, UniProt Q9NY46) has 54 drugs tested at it and 11 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NY46
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
- Registered trials of its drugs
- 2,666
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 44 |
| Active | 3 |
| Went quiet | 6 |
| Withdrawn from market | 1 |
| Total | 54 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lidocaine | Marketed | Phase 4 | none listed |
| Ropivacaine | Marketed | Phase 4 | none listed |
| Topiramate | Marketed | Phase 4 | none listed |
| Lamotrigine | Marketed | Phase 4 | none listed |
| Carbamazepine | Marketed | Phase 4 | none listed |
| Lacosamide | Marketed | Phase 4 | Ended 2026 |
| Riluzole | Marketed | Phase 4 | none listed |
| Tetracaine | Marketed | Phase 4 | none listed |
| Eslicarbazepine acetate | Marketed | Phase 4 | Ended 2026 |
| Zonisamide | Marketed | Phase 4 | none listed |
| Phenytoin | Marketed | Phase 4 | none listed |
| Articaine | Marketed | Phase 4 | none listed |
12 of 54 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 6 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Novartis | Route B |
| GSK | Route B |
| Azurity Pharmaceuticals | Route B |
The other 8 companies at SCN3A
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at SCN3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.